Commit Biologics ("Commit"), a pioneer in the activation of the complement system to treat autoimmune disease and cancer, today announces ...

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s bispecific antibody targeting PD-L1 and VEGF-A, BNT-327, in a deal possibly worth over $11 billion. The companies will ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

CHICAGO -- Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients ...

US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.

The new data from the Phase 3 C-POST trial presented at ASCO 2025 demonstrated that cemiplimab (Libtayo) reduced the risk of ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Regeneron (NASDAQ:REGN) shares fell ~18% to reach a new 52-week low as a Phase 3 trial failure for its antibody therapy itepekimab, developed with Sanofi (SNY) for a lung disorder known as chronic ...